RRx-001
Modify Date: 2024-01-02 16:05:16
RRx-001 structure
|
Common Name | RRx-001 | ||
|---|---|---|---|---|
| CAS Number | 925206-65-1 | Molecular Weight | 268.02200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C5H6BrN3O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RRx-001RRx-001 is a potent inhibitor of G6PD. RRx-001 shows potent antimalarial, although as a single agent, the drug sensitivity testing indicated that higher dose of RRx-001 was required to inhibited 50 % of the parasite's activity (IC50 = 0.14 ± 0.04 ug/ml).IC50 value: 0.14 ± 0.04 ug/ml [1]Target: G6PDin vitro: RRx-001 is a novel, systemically non-toxic, epigenetic anticancer agent for multiple tumour types, with activity mediated through increased nitric oxide (NO) production and PPP inhibition. [1]in vivo: RRx-001is a novel, nonexplosive molecule modified from a class of solid rocket propellants, has shown promise as a novel cancer therapeutic agent in a number of cell lines and tumor models. In mouse models, RRx-001 administered intravenously as a single agent was equipotent to cisplatin while better tolerated. RRx-001 also showed activity as a radiosensitizer in both in vitro and in vivo models. The activity of RRx-001 is thought to be associated with a nucleophilic substitution by circulating thiol compounds and covalent binding of RRx-001 to cysteinyl residues in Hb, followed by the generation of nitrogen oxides. [2] |
| Name | 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
|---|---|
| Synonym | More Synonyms |
| Description | RRx-001 is a potent inhibitor of G6PD. RRx-001 shows potent antimalarial, although as a single agent, the drug sensitivity testing indicated that higher dose of RRx-001 was required to inhibited 50 % of the parasite's activity (IC50 = 0.14 ± 0.04 ug/ml).IC50 value: 0.14 ± 0.04 ug/ml [1]Target: G6PDin vitro: RRx-001 is a novel, systemically non-toxic, epigenetic anticancer agent for multiple tumour types, with activity mediated through increased nitric oxide (NO) production and PPP inhibition. [1]in vivo: RRx-001is a novel, nonexplosive molecule modified from a class of solid rocket propellants, has shown promise as a novel cancer therapeutic agent in a number of cell lines and tumor models. In mouse models, RRx-001 administered intravenously as a single agent was equipotent to cisplatin while better tolerated. RRx-001 also showed activity as a radiosensitizer in both in vitro and in vivo models. The activity of RRx-001 is thought to be associated with a nucleophilic substitution by circulating thiol compounds and covalent binding of RRx-001 to cysteinyl residues in Hb, followed by the generation of nitrogen oxides. [2] |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C5H6BrN3O5 |
|---|---|
| Molecular Weight | 268.02200 |
| Exact Mass | 266.94900 |
| PSA | 111.95000 |
| LogP | 0.45750 |
| Storage condition | -20℃ |
| Hazard Codes | N |
|---|
|
~83%
RRx-001 CAS#:925206-65-1 |
| Literature: Straessler, Nichols A.; Lesley, Michael W.; Cannizzo, Louis F. Organic Process Research and Development, 2012 , vol. 16, # 3 p. 512 - 517 |
| RRX-001 |
| UNII-7RPW6SU9SC |
| 1-bromoacetyl-3,3-dinitroazetidine |
| 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one |